- Title: Subtitle
- Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma
- Creators
- Frederick Lundry Locke - Moffitt Cancer CenterArmin Ghobadi - Washington University in St. LouisCaron A. Jacobson - Dana-Farber Cancer InstituteEric D. Jacobsen - Dana-Farber Cancer Institute, Boston, MADavid Bernard Miklos - Stanford UniversityLazaros J. Lekakis - University of Miami Health SystemIra Braunschweig - Albert Einstein College of MedicineOlalekan O. Oluwole - Vanderbilt UniversityYi Lin - Mayo Clinic Rochester, MNTanya Siddiqi - City Of Hope National Medical CenterAbhinav Deol - Wayne State UniversityPatrick Michael Reagan - University of Rochester Medical CenterUmar Farooq - University of IowaAdrian Bot - Whitney Museum of American ArtYizhou Jiang - KiteJohn M. Rossi - KiteAllen Xue - Whitney Museum of American ArtWilliam Y. Go - Whitney Museum of American ArtSattva Swarup Neelapu - The University of Texas MD Anderson Cancer Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.3003-3003
- DOI
- 10.1200/JCO.2018.36.15_suppl.3003
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362752902771
Abstract
Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma
Journal of clinical oncology, Vol.36(15_suppl), pp.3003-3003
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.3003
Details
Metrics
6 Record Views